# bioMérieux

Source: https://onco.cc/companies/biomerieux/  
OnCo record `biomerieux` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

French in vitro diagnostics company, best known for infection testing, whose THxID BRAF kit was a companion diagnostic for melanoma drugs.

## Summary

bioMérieux describes itself as a world leader in in vitro diagnostics and dates its history to 1963 and the Mérieux family; its press releases are datelined Marcy-l'Étoile, France. Most of its products test for infections. In oncology its US arm held the approval for the THxID BRAF Kit (2013), a companion diagnostic for dabrafenib, trametinib and later encorafenib with binimetinib in melanoma, which the FDA PMA database records as withdrawn in June 2024.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: bioMerieux
- HQ: Marcy-l'Étoile
- Type: diagnostics
- Website: https://www.biomerieux.com

## Sources

- Official website: https://www.biomerieux.com
- FDA PMA P120014: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120014

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/)
- drugs: [THxID BRAF Kit](https://onco.cc/drugs/thxid-braf/)

---
JSON: https://onco.cc/api/v1/entities/biomerieux.json